Takeda Pharmaceutical Company Ltd Statement re Applicable Exchange Rate (8137M)
January 11 2019 - 2:00AM
UK Regulatory
TIDM0RN3 TIDMTTM
RNS Number : 8137M
Takeda Pharmaceutical Company Ltd
11 January 2019
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO
WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH
JURISDICTION
FOR IMMEDIATE RELEASE
Takeda Announces Applicable Exchange Rate Under Currency
Conversion Facility
Osaka, Japan - January 11, 2019 - Takeda Pharmaceutical Company
Limited (TSE: 4502) (NYSE: TAK) ("Takeda") today announces the
Applicable Exchange Rate (as defined below) in connection with its
recommended acquisition of Shire plc ("Shire") (the
"Acquisition").
As set out in the scheme document published by Shire on November
12, 2018 (the "Scheme Document"), any Shire Shareholder who has
made (or is deemed to have made) an Election to receive the US
Dollar cash portion of the Consideration payable to them under the
Scheme in pounds Sterling under the Currency Conversion Facility
will receive the cash portion of the Consideration payable to them
in pounds Sterling (net of any applicable customary transaction and
dealing costs associated with the conversion) at the applicable
market exchange rate on the latest reasonably practicable date for
fixing such rate before the relevant payment date under the
Currency Conversion Facility (such rate the "Applicable Exchange
Rate").
Takeda hereby announces that the Applicable Exchange Rate is a
US Dollar ("USD") / pound Sterling ("GBP") rate of GBP 0.7842 for
each USD 1.00 and, therefore, that each relevant Shire Shareholder
is entitled to receive GBP 23.78 for each Scheme Share held.
As set out in the expected timetable of principal events
relating to the Scheme on pages 1 to 3 of the Scheme Document,
settlement of the cash portion of the Consideration will be
effected through the making of payments in CREST, electronic BACs
transfers or the despatch of cheques, as applicable, in each case
by January 22, 2019 (being 14 calendar days from the Effective
Date).
Defined terms used, but not defined, in this announcement have
the meanings set out in the Scheme Document.
Takeda (Investor Relations)
Takashi Okubo
takeda.ir.contact@takeda.com
+81 3 3278 2306
Takeda (Media - inside Japan)
Kazumi Kobayashi
Kazumi.Kobayashi@takeda.com
+81 3 3278 2095
Takeda (Media - outside Japan)
Tsuyoshi Tada
Tsuyoshi.Tada@takeda.com
+1 617 551 2933
Elissa Johnsen
Elissa.Johnsen@takeda.com
+1 312 285 3203
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502) (NYSE:TAK) is a
global, values-based, R&D-driven biopharmaceutical leader
headquartered in Japan, committed to bringing better health and a
brighter future to patients by translating science into
highly-innovative medicines. Takeda focuses its R&D efforts on
four therapeutic areas: Oncology, Gastroenterology (GI),
Neuroscience and Rare Diseases. We also make targeted R&D
investment in Plasma-Derived Therapies and Vaccines. We are
focusing on developing highly innovative medicines that contribute
to make a difference in people's lives by advancing the frontier of
new treatment options, through our enhanced collaborative R&D
engine and capabilities to create a robust, modality-diverse
pipeline. Our employees are committed to improving quality of life
for patients, working with our partners in health care in
approximately 80 countries and regions.
For more information, visit https://www.takeda.com
# # #
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
STRGMGMMLGKGLZM
(END) Dow Jones Newswires
January 11, 2019 02:00 ET (07:00 GMT)
Takeda Pharmaceutical (LSE:0RN3)
Historical Stock Chart
From Sep 2024 to Oct 2024
Takeda Pharmaceutical (LSE:0RN3)
Historical Stock Chart
From Oct 2023 to Oct 2024